Skip to main content
Premium Trial:

Request an Annual Quote

System Biosciences Taps Maverix's Platform for Exosome Sequence Analytics Service

Premium

System Biosciences has selected Maverix Biomics' bioinformatics platform to provide the data analysis component of its company's newly launched exosome RNA sequence analytics service, dubbed Exo-NGS.

Under the terms of the arrangement, customers of SBI's service will be able to use Maverix's cloud-based next generation sequence data management, exploration, and visualization platform (BI 11/9/2012) to identify and analyze exosome-associated RNA biomarkers.

The cloud solution includes features such as library sequence quality control metrics, tools for relative RNA abundance and identity analysis, differential expression analysis, and data visualization capabilities such as RNA type charts, expression heatmaps. Users also have access to resources such as the ENCODE data which allows them to explore their data in the context of public datasets.

The financial terms of the agreement are not being disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.